메뉴 건너뛰기




Volumn 20, Issue 9, 2008, Pages 482-489

Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

EID: 50849087659     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (6)

References (43)
  • 1
    • 4644308426 scopus 로고    scopus 로고
    • Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • 3 Suppl:188S-203S
    • Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):188S-203S.
    • (2004) Chest , pp. 126
    • Hirsh, J.1    Raschke, R.2
  • 2
    • 0037453968 scopus 로고    scopus 로고
    • REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
    • Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
    • (2003) JAMA , vol.289 , pp. 853-863
    • Lincoff, A.M.1    Bittl, J.A.2    Harrington, R.A.3
  • 3
    • 20144373165 scopus 로고    scopus 로고
    • ASPIRE Investigators. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: A randomized evaluation (ASPIRE) pilot trial
    • Mehta SR, Steg PG, Granger CB, et al.; ASPIRE Investigators. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: A randomized evaluation (ASPIRE) pilot trial. Circulation 2005;111:1390-1397.
    • (2005) Circulation , vol.111 , pp. 1390-1397
    • Mehta, S.R.1    Steg, P.G.2    Granger, C.B.3
  • 4
    • 33748431522 scopus 로고    scopus 로고
    • STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    • Montalescot G, White HD, Gallo R, et al; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-1017.
    • (2006) N Engl J Med , vol.355 , pp. 1006-1017
    • Montalescot, G.1    White, H.D.2    Gallo, R.3
  • 5
    • 3042784252 scopus 로고    scopus 로고
    • Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: A systematic overview
    • Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: A systematic overview. JAMA 2004;292:89-96.
    • (2004) JAMA , vol.292 , pp. 89-96
    • Petersen, J.L.1    Mahaffey, K.W.2    Hasselblad, V.3
  • 6
    • 33845323043 scopus 로고    scopus 로고
    • Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
    • White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006;152:1042-1050.
    • (2006) Am Heart J , vol.152 , pp. 1042-1050
    • White, H.D.1    Kleiman, N.S.2    Mahaffey, K.W.3
  • 7
    • 33645515458 scopus 로고    scopus 로고
    • ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction
    • Antman EM, Morrow DA, McCabe CH, et al; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-1488.
    • (2006) N Engl J Med , vol.354 , pp. 1477-1488
    • Antman, E.M.1    Morrow, D.A.2    McCabe, C.H.3
  • 8
    • 0037021568 scopus 로고    scopus 로고
    • A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
    • Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.
    • (2002) J Am Coll Cardiol , vol.40 , pp. 1943-1950
    • Choussat, R.1    Montalescot, G.2    Collet, J.P.3
  • 9
    • 0035318112 scopus 로고    scopus 로고
    • NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
    • Kereiakes DJ, Grines C, Fry E, et al; NICE 1 and NICE 4 Investigators. National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-278.
    • (2001) J Invasive Cardiol , vol.13 , pp. 272-278
    • Kereiakes, D.J.1    Grines, C.2    Fry, E.3
  • 10
    • 0036678547 scopus 로고    scopus 로고
    • Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention
    • Chen WH, Lau CP, Lau YK, et al. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002;14:439-442.
    • (2002) J Invasive Cardiol , vol.14 , pp. 439-442
    • Chen, W.H.1    Lau, C.P.2    Lau, Y.K.3
  • 11
    • 0036246812 scopus 로고    scopus 로고
    • Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes
    • Miller L, Gupta A, Bertolet BD. Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. J Invasive Cardiol 2002;14:247-250.
    • (2002) J Invasive Cardiol , vol.14 , pp. 247-250
    • Miller, L.1    Gupta, A.2    Bertolet, B.D.3
  • 12
    • 0010909678 scopus 로고    scopus 로고
    • Enoxaparin anticoagulation for percutaneous coronary interventions: A pilot safety study
    • Díez JG, Lievano MJ, Olaya CA, et al. Enoxaparin anticoagulation for percutaneous coronary interventions: A pilot safety study. Circulation 1999;100:968.
    • (1999) Circulation , vol.100 , pp. 968
    • Díez, J.G.1    Lievano, M.J.2    Olaya, C.A.3
  • 13
    • 0032711331 scopus 로고    scopus 로고
    • Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
    • Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.
    • (1999) Am J Cardiol , vol.84 , pp. 1391-1395
    • Rabah, M.M.1    Premmereur, J.2    Graham, M.3
  • 14
    • 0035684022 scopus 로고    scopus 로고
    • Drozd J, Opalifska E, Wójcik J, Madejczyk A. The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina. Kardiol Pol 2001;55:520-524.
    • Drozd J, Opalifska E, Wójcik J, Madejczyk A. The use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina. Kardiol Pol 2001;55:520-524.
  • 15
    • 0007840637 scopus 로고    scopus 로고
    • Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions
    • Abstract TCT-34
    • Dudek D, Dabrowski M, Ochala A, et al. Multicenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions. Am J Cardiol 2000;86(8 Suppl 1):15i, Abstract TCT-34.
    • (2000) Am J Cardiol , vol.86 , Issue.8 SUPPL. 1
    • Dudek, D.1    Dabrowski, M.2    Ochala, A.3
  • 16
    • 0037221893 scopus 로고    scopus 로고
    • Coronary revascularization using integrilin and single bolus enoxaparin study. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study
    • Bhatt DL, Lee BI, Casterella PJ, et al. Coronary revascularization using integrilin and single bolus enoxaparin study. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 2003;41:20-25.
    • (2003) J Am Coll Cardiol , vol.41 , pp. 20-25
    • Bhatt, D.L.1    Lee, B.I.2    Casterella, P.J.3
  • 17
    • 0005153085 scopus 로고    scopus 로고
    • Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: A randomized study
    • Galeote G, Hussein M, Sobrino N, et al. Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: A randomized study. Eur Heart J 2001;22( Suppl):663.
    • (2001) Eur Heart J , vol.22 , Issue.SUPPL. , pp. 663
    • Galeote, G.1    Hussein, M.2    Sobrino, N.3
  • 18
    • 21144439571 scopus 로고    scopus 로고
    • Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial)
    • Madan M, Radhakrishnan S, Reis M, et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol 2005;95:1295-1301.
    • (2005) Am J Cardiol , vol.95 , pp. 1295-1301
    • Madan, M.1    Radhakrishnan, S.2    Reis, M.3
  • 19
    • 20344374735 scopus 로고    scopus 로고
    • Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis
    • Borentain M, Montalescot G, Bouzamondo A, et al. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis. Catheter Cardiovasc Interv 2005;65:212-221.
    • (2005) Catheter Cardiovasc Interv , vol.65 , pp. 212-221
    • Borentain, M.1    Montalescot, G.2    Bouzamondo, A.3
  • 21
    • 33645498094 scopus 로고    scopus 로고
    • Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes
    • Yusuf S, Mehta SR, Chrolavicius S, et al; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476.
    • (2006) N Engl J Med , vol.354 , pp. 1464-1476
    • Yusuf, S.1    Mehta, S.R.2    Chrolavicius, S.3
  • 22
    • 37148999983 scopus 로고    scopus 로고
    • Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention-Quantitative review of randomized trials
    • Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention-Quantitative review of randomized trials. Arch Intern Med 2007;167:2423-2430.
    • (2007) Arch Intern Med , vol.167 , pp. 2423-2430
    • Dumaine, R.1    Borentain, M.2    Bertel, O.3
  • 23
    • 3342901810 scopus 로고    scopus 로고
    • Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin
    • Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-398.
    • (2004) Circulation , vol.110 , pp. 392-398
    • Montalescot, G.1    Collet, J.P.2    Tanguy, M.L.3
  • 24
    • 0036306824 scopus 로고    scopus 로고
    • Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries
    • Gilchrist IC, Berkowitz SD, Thompson TD, et al. Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. Am Heart J 2002;144:73-80.
    • (2002) Am Heart J , vol.144 , pp. 73-80
    • Gilchrist, I.C.1    Berkowitz, S.D.2    Thompson, T.D.3
  • 25
    • 33645991543 scopus 로고    scopus 로고
    • Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin
    • Zalc S, Lemos PA, Esteves A, et al. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin. J Invasive Cardiol 2006;18:45-48.
    • (2006) J Invasive Cardiol , vol.18 , pp. 45-48
    • Zalc, S.1    Lemos, P.A.2    Esteves, A.3
  • 26
    • 33644872364 scopus 로고    scopus 로고
    • Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-175.
    • Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-175.
  • 27
    • 21444448302 scopus 로고    scopus 로고
    • What is the proper activated clotting time (ACT) at which to remove a femoral sheath after PCI? What are the best "protocols" for sheath removal?
    • Galli A, Palatnik A. What is the proper activated clotting time (ACT) at which to remove a femoral sheath after PCI? What are the best "protocols" for sheath removal? Crit Care Nurse 2005;25:88-92, 94-95.
    • (2005) Crit Care Nurse , vol.25 , Issue.88-92 , pp. 94-95
    • Galli, A.1    Palatnik, A.2
  • 28
    • 1442310124 scopus 로고    scopus 로고
    • Frequency and timing of activated clotting time levels for sheath removal
    • Niederstadt JA. Frequency and timing of activated clotting time levels for sheath removal. J Nurs Care Qual 2004;19:34-38.
    • (2004) J Nurs Care Qual , vol.19 , pp. 34-38
    • Niederstadt, J.A.1
  • 29
    • 0033192795 scopus 로고    scopus 로고
    • Nursing interventions to decrease bleeding at the femoral access site after percutaneous coronary intervention. SANDBAG Nursing Coordinators. Standards of Angioplasty Nursing techniques to Diminish Bleeding Around the Groin
    • Juran NB, Rouse CL, Smith DD, et al. Nursing interventions to decrease bleeding at the femoral access site after percutaneous coronary intervention. SANDBAG Nursing Coordinators. Standards of Angioplasty Nursing techniques to Diminish Bleeding Around the Groin. Am J Crit Care 1999;8:303-313.
    • (1999) Am J Crit Care , vol.8 , pp. 303-313
    • Juran, N.B.1    Rouse, C.L.2    Smith, D.D.3
  • 30
    • 0035814785 scopus 로고    scopus 로고
    • Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris
    • Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
    • (2001) Circulation , vol.103 , pp. 658-663
    • Collet, J.P.1    Montalescot, G.2    Lison, L.3
  • 31
    • 0742270477 scopus 로고    scopus 로고
    • Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study
    • Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61:163-170.
    • (2004) Catheter Cardiovasc Interv , vol.61 , pp. 163-170
    • Martin, J.L.1    Fry, E.T.2    Sanderink, G.J.3
  • 32
    • 0141502511 scopus 로고    scopus 로고
    • ELECT Investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study
    • Moliterno DJ, Hermiller JB, Kereiakes DJ, et al; ELECT Investigators. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42:1132-1139.
    • (2003) J Am Coll Cardiol , vol.42 , pp. 1132-1139
    • Moliterno, D.J.1    Hermiller, J.B.2    Kereiakes, D.J.3
  • 33
    • 0030992622 scopus 로고    scopus 로고
    • Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
    • The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators
    • The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
    • (1997) J Am Coll Cardiol , vol.29 , pp. 1474-1482
  • 34
    • 7244251497 scopus 로고    scopus 로고
    • Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention
    • Díez JG, Cheong BY, O'Meallie LP, Alt EU. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. J Intervent Cardiol 2004;17:307-313.
    • (2004) J Intervent Cardiol , vol.17 , pp. 307-313
    • Díez, J.G.1    Cheong, B.Y.2    O'Meallie, L.P.3    Alt, E.U.4
  • 35
    • 0642314375 scopus 로고    scopus 로고
    • Enoxaparin in percutaneous interventions: When to monitor? A case series
    • Cheong B, O'Meallie L, Díez JG. Enoxaparin in percutaneous interventions: When to monitor? A case series. J Invasive Cardiol 2003;15:(Suppl)1-6.
    • (2003) J Invasive Cardiol , vol.15 , Issue.SUPPL. , pp. 1-6
    • Cheong, B.1    O'Meallie, L.2    Díez, J.G.3
  • 36
    • 4444343689 scopus 로고    scopus 로고
    • Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: Implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention
    • Levine GN, Ferrando T. Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: Implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis 2004;17:167-171.
    • (2004) J Thromb Thrombolysis , vol.17 , pp. 167-171
    • Levine, G.N.1    Ferrando, T.2
  • 37
    • 0036790778 scopus 로고    scopus 로고
    • Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions
    • Aslam MS, Sundberg S, Sabri MN, et al. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2002;57:187-190.
    • (2002) Catheter Cardiovasc Interv , vol.57 , pp. 187-190
    • Aslam, M.S.1    Sundberg, S.2    Sabri, M.N.3
  • 38
    • 26444511607 scopus 로고    scopus 로고
    • Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: A population model analysis
    • Sanchez-Pena P, Hulot JS, Urien S, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: A population model analysis. Br J Clin Pharmacol 2005;60:364-373.
    • (2005) Br J Clin Pharmacol , vol.60 , pp. 364-373
    • Sanchez-Pena, P.1    Hulot, J.S.2    Urien, S.3
  • 39
    • 50849115611 scopus 로고    scopus 로고
    • sanofi-aventis US. Lovenox® (enoxaparin sodium injection) product information, 2007. Available: http://products.sanofi-aventis.us/lovenox/lovenox. pdf. Accessed December 11, 2007.
    • sanofi-aventis US. Lovenox® (enoxaparin sodium injection) product information, 2007. Available: http://products.sanofi-aventis.us/lovenox/lovenox. pdf. Accessed December 11, 2007.
  • 40
    • 4644295940 scopus 로고    scopus 로고
    • Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):576S-599S.
    • Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):576S-599S.
  • 41
    • 3042782723 scopus 로고    scopus 로고
    • SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial
    • Ferguson JJ, Califf RM, Antman EM, et al.; SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
    • (2004) JAMA , vol.292 , pp. 45-54
    • Ferguson, J.J.1    Califf, R.M.2    Antman, E.M.3
  • 42
    • 33748950070 scopus 로고    scopus 로고
    • SYNERGY Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
    • Cohen M, Mahaffey KW, Pieper K, et al.; SYNERGY Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: Enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006;48:1346-1354.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 1346-1354
    • Cohen, M.1    Mahaffey, K.W.2    Pieper, K.3
  • 43
    • 34249824588 scopus 로고    scopus 로고
    • ExTRACT-TIMI 25 Investigators. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    • Gibson CM, Murphy SA, Montalescot G, et al.; ExTRACT-TIMI 25 Investigators. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007;49:2238-2246.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 2238-2246
    • Gibson, C.M.1    Murphy, S.A.2    Montalescot, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.